Treatment of Akt inhibitors leads to tumor stasis instead of regression in preclinical models, and most patients either have partial or minimal responses from Akt inhibition in clinical trials (Llovet and Hernandez‐Gea, 2014). This evidence concerns the gene AKT1 and neoplasm.